WO2010022055A3 - Inhibiteurs de canaux sodiques sensibles au potentiel - Google Patents

Inhibiteurs de canaux sodiques sensibles au potentiel Download PDF

Info

Publication number
WO2010022055A3
WO2010022055A3 PCT/US2009/054169 US2009054169W WO2010022055A3 WO 2010022055 A3 WO2010022055 A3 WO 2010022055A3 US 2009054169 W US2009054169 W US 2009054169W WO 2010022055 A3 WO2010022055 A3 WO 2010022055A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
chronic pain
pain disorders
derivatives useful
ine derivatives
Prior art date
Application number
PCT/US2009/054169
Other languages
English (en)
Other versions
WO2010022055A2 (fr
Inventor
John L. Buchanan
Howard Bregman
Nagasree Chakka
Erin F. Dimauro
Bingfan Du
Hanh Nho Nguyen
Xiao Mei Zheng
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of WO2010022055A2 publication Critical patent/WO2010022055A2/fr
Publication of WO2010022055A3 publication Critical patent/WO2010022055A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention porte sur des composés qui sont des inhibiteurs de canal sodique sensible au potentiel (Nav), en particulier Nav 1.7 et sont particulièrement utiles pour le traitement de maladies pouvant être traitées par l'inhibition de ces canaux, en particulier, des troubles de douleur chronique. L'invention porte également sur des compositions pharmaceutiques contenant de tels composés et sur des procédés pour préparer de tels composés.
PCT/US2009/054169 2008-08-20 2009-08-18 Inhibiteurs de canaux sodiques sensibles au potentiel WO2010022055A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18950108P 2008-08-20 2008-08-20
US61/189,501 2008-08-20
US19601208P 2008-10-14 2008-10-14
US61/196,012 2008-10-14

Publications (2)

Publication Number Publication Date
WO2010022055A2 WO2010022055A2 (fr) 2010-02-25
WO2010022055A3 true WO2010022055A3 (fr) 2010-06-17

Family

ID=41707632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/054169 WO2010022055A2 (fr) 2008-08-20 2009-08-18 Inhibiteurs de canaux sodiques sensibles au potentiel

Country Status (1)

Country Link
WO (1) WO2010022055A2 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103196A1 (fr) * 2010-02-17 2011-08-25 Amgen Inc. Dérivés d'arylcarboxamide en tant qu'inhibiteurs de canal sodique pour le traitement de la douleur
AU2010346633B2 (en) * 2010-02-24 2015-12-03 Research Triangle Institute Arylpiperazine opioid receptor antagonists
US8486647B2 (en) 2010-06-09 2013-07-16 Regeneron Pharmaceuticals, Inc. Neuropeptide release assay for sodium channels
US8871996B2 (en) 2010-06-09 2014-10-28 Regeneron Pharmaceuticals, Inc. Mice expressing human voltage-gated sodium channels
CN102344407A (zh) * 2010-08-03 2012-02-08 艾琪康医药科技（上海）有限公司 一种3-氟哌啶衍生物及其制备方法
EP2616465B1 (fr) * 2010-09-13 2015-11-04 Novartis AG Triazine-oxadiazoles
EP2680852A1 (fr) 2011-03-02 2014-01-08 Lead Discovery Center GmbH Dérivés de triazine disubstitués pharmaceutiquement actifs
CN103562184B (zh) * 2011-03-02 2016-04-27 利德探索中心有限公司 药学活性的二取代的吡啶衍生物
CN102285969B (zh) * 2011-06-28 2013-06-19 山东大学 N-1-取代哌啶-4-芳胺类衍生物及其制备方法与应用
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
WO2013064983A1 (fr) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques
CA2874621A1 (fr) 2012-05-22 2013-11-28 Genentech, Inc. Benzamides n-substitues et leur utilisation dans le traitement de la douleur
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
JP6359560B2 (ja) * 2012-12-31 2018-07-18 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 複素環式化合物及びその使用方法
US9040712B2 (en) * 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
WO2014127116A1 (fr) * 2013-02-13 2014-08-21 Novartis Ag Agents analgésiques oculaires topiques
WO2014153037A1 (fr) 2013-03-14 2014-09-25 Genentech, Inc. Triazolopyridines substituées et leurs procédés d'utilisation
WO2014160521A1 (fr) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Dérivés de pipérazine et leur utilisation comme modulateurs de kit
RU2015143834A (ru) 2013-03-15 2017-04-24 Дженентек, Инк. Замещенные бензоксазолы и способы их применения
GB2516303A (en) * 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
EP3039019B1 (fr) * 2013-08-26 2020-04-22 Purdue Pharma L.P. Dérivés d'azaspiro[4.5]décane et leur utilisation
WO2015050212A1 (fr) * 2013-10-02 2015-04-09 日産化学工業株式会社 Inhibiteur du canal calcique de type t
WO2015058129A1 (fr) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Composés à utiliser pour traiter des troubles associés à l'enzyme kit
WO2015057873A1 (fr) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions utiles pour le traitement de troubles associés à l'enzyme kit
PE20161247A1 (es) 2013-11-27 2016-11-30 Genentech Inc Benzamidas sustituidas y metodos para usarlas
WO2015123398A1 (fr) * 2014-02-12 2015-08-20 Purdue Pharma L.P. Dérivés d'isoquinoline et leur utilisation
JP6152229B2 (ja) * 2014-03-17 2017-06-21 ファイザー・インク 代謝性および関連障害の処置において使用するためのジアシルグリセロールアシルトランスフェラーゼ２阻害剤
CN104016977B (zh) * 2014-06-13 2016-06-22 山东大学 一种取代噻二嗪二酮类衍生物及其制备方法与应用
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
WO2016022569A1 (fr) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Composés utiles pour traiter des troubles associés à kit
PE20180575A1 (es) 2015-05-22 2018-04-04 Genentech Inc Benzamidas sustituidas y metodos para utilizarlas
JP2018521076A (ja) 2015-07-24 2018-08-02 ブループリント メディシンズ コーポレイション Ｋｉｔ及びｐｄｇｆｒに関連する疾病を治療するのに有用な化合物
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
PE20181003A1 (es) 2015-09-28 2018-06-26 Genentech Inc Compuestos terapeuticos y sus metodos de uso
JP2018535234A (ja) 2015-11-25 2018-11-29 ジェネンテック， インコーポレイテッド ナトリウムチャネル遮断薬として有用な置換ベンズアミド
CN105837525B (zh) * 2016-03-25 2019-05-28 浙江工业大学 2,4-二胺-1,3,5-三嗪类化合物及其制备方法与应用
JP2019513714A (ja) 2016-03-30 2019-05-30 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
SG11201903348UA (en) 2016-10-17 2019-05-30 Genentech Inc Therapeutic compounds and methods of use thereof
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
PT3541784T (pt) 2016-11-18 2023-11-22 Integrative Res Laboratories Sweden Ab Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical
EP3555064B9 (fr) 2016-12-16 2023-03-01 Pfizer Inc. Agonistes du récepteur glp-1 et leurs utilisations
WO2018175707A1 (fr) 2017-03-24 2018-09-27 Genentech, Inc. Dérivés de 4-pipéridine-n-(pyrimidin-4-yl) chromane-7-sulfonamide en tant qu'inhibiteurs de canaux sodiques
CN106995380B (zh) * 2017-03-31 2018-12-28 九江善水科技股份有限公司 一种2-氨基-4-硝基苯酚的合成方法
WO2018183712A1 (fr) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Composés de pyrrolo[1,2-b]pyridazine et compositions utiles pour traiter des troubles liés à kit et pdgfr
WO2019018795A1 (fr) * 2017-07-20 2019-01-24 Yumanity Therapeutics Composés et utilisations de ces composés
WO2019084157A1 (fr) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Composés et utilisations de ces composés
US11028075B2 (en) 2018-02-26 2021-06-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2019191702A1 (fr) 2018-03-30 2019-10-03 F. Hoffmann-La Roche Ag Hydro-pyrido-azines substituées utilisées comme inhibiteurs du canal sodique
EP3784234A1 (fr) 2018-04-25 2021-03-03 Yumanity Therapeutics, Inc. Composés et leurs utilisations
SI3856341T1 (sl) 2019-04-12 2024-02-29 Blueprint Medicines Corporation Kristalinične oblike (s)-1-(4-fluorofenila)-1-(2-(4-(6-(1-metil-1h- pirazola-4-il)pirolo(2,1-f)(1,2,4)triazin-4-il)piperazinil)-pirimidin- 5-il)etan-1-amin in postopki izdelave
TW202104231A (zh) 2019-04-12 2021-02-01 美商藍印藥品公司 用於治療kit 及pdgfra 介導之疾病的組合物及方法
CN111057021B (zh) * 2019-12-11 2023-05-23 中国药科大学 均三嗪类化合物及其制备方法和用途
US20230078941A1 (en) * 2019-12-23 2023-03-16 Lg Chem, Ltd. Novel amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof
AU2020413583B2 (en) * 2019-12-23 2023-12-14 Lg Chem, Ltd. Novel amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof
WO2023132208A1 (fr) * 2022-01-07 2023-07-13 国立大学法人大阪大学 Composition pharmaceutique destinée à prévenir ou à traiter l'insuffisance cardiaque
WO2023229685A2 (fr) * 2022-02-24 2023-11-30 Microbiotix, Inc. Inhibiteurs à large spectre de cytomégalovirus
CN117384091B (zh) * 2023-12-08 2024-02-20 四川大学华西第二医院 一类酰胺衍生物、合成方法及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083653A1 (fr) * 2001-04-11 2002-10-24 Amgen Inc. Derives d'acrylamide de triazinyle utilises comme inhibiteur de kinase
WO2002092576A1 (fr) * 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Derives de diaryluree utilisables en tant qu'agents anti-inflammatoires

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083653A1 (fr) * 2001-04-11 2002-10-24 Amgen Inc. Derives d'acrylamide de triazinyle utilises comme inhibiteur de kinase
WO2002092576A1 (fr) * 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Derives de diaryluree utilisables en tant qu'agents anti-inflammatoires

Also Published As

Publication number Publication date
WO2010022055A2 (fr) 2010-02-25

Similar Documents

Publication Publication Date Title
WO2010022055A3 (fr) Inhibiteurs de canaux sodiques sensibles au potentiel
WO2009012242A3 (fr) Inhibiteurs des canaux sodiques
WO2007095124A3 (fr) Derives, compositions de benzazole et procedes d'utilisation en tant qu'inhibiteurs de la kinase aurora
WO2006107451A3 (fr) Derives d'honokiol pour traiter les maladies proliferantes
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
WO2005086656A3 (fr) Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
WO2010017545A3 (fr) Composés de triazole qui modulent l'activité hsp90
WO2005110994A3 (fr) Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
WO2008135826A3 (fr) Dérivés de la pyridine
WO2007021941A3 (fr) Inhibiteurs des canaux sodium sensibles au voltage
WO2008089307A3 (fr) Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer
WO2006135627A3 (fr) Inhibiteurs de l'activite akt
WO2005111039A3 (fr) Composés et procée pour l'inhibition de progression mitotique
WO2008147797A3 (fr) Modulateurs de canal ionique et leurs procédés d'utilisation
WO2009076454A3 (fr) Compositions qui modulant le calcium intracellulaire
WO2008070041A3 (fr) Inhibiteurs de l'activité akt
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
MX346186B (es) Inhibidores de proteina cinasas.
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2005046603A3 (fr) Composes pyridiniques
WO2006034154A3 (fr) Sels de 5-azacytidine
WO2008021038A3 (fr) Pyridobenzazépines et méthodes d'inhibition de la progression mitotique
WO2010011772A3 (fr) Inhibiteurs de la pyrazolopyridine kinase tricyclique
WO2008097924A3 (fr) Compositions pharmaceutiques comprenant des analogues du dextrométhorphane pour le traitement de troubles neurologiques

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09791616

Country of ref document: EP

Kind code of ref document: A2